Skip to main content
. 2016 Mar 7;7(15):20357–20367. doi: 10.18632/oncotarget.7952

Table 1. The association of promising SNPs of NER pathway genes with hepatocellular cancer risk.

Gene SNP Genotype Stage 1 Stage 2 Meta
Cases (%) Controls (%) Pa OR (95%CI) Cases (%) Controls (%) Pa OR(95%CI) Pa OR (95%CI)
n = 169 n = 501 n = 401 n = 401
Recognition-related
XPA rs10817938 n = 353 n = 379
TT 105 (62.1) 311 (62.1) 1(Ref.) 208 (58.9) 241 (63.6) 1 (Ref.)
TC 51 (30.2) 172 (34.3) 0.525 0.88 (0.60–1.30) 129 (36.5) 124 (32.7) 0.263 1.19 (0.88–1.63) 0.537 1.08 (0.85–1.36)
CC 13 (7.7) 15 (3.0) 0.020 2.52 (1.16–5.49) 16 (4.5) 14 (3.5) 0.098 2.04 (0.88–4.73) 0.038 1.76 (1.03–3.01)
CC+CT vs. TT 0.956 1.01 (0.70–1.45) 0.146 1.25 (0.93–1.69) 0.260 1.14 (0.91–1.42)
CC vs. TT+TC 0.012 2.66 (1.24–5.74) 0.136 1.88 (0.82–4.33) 0.045 1.72 (1.01–2.91)
XPC rs1870134 n = 359 n = 381
GG 88 (52.1) 257 (51.3) 1 (Ref.) 230 (64.1) 197 (51.7) 1 (Ref.)
GC 76 (45.0) 204 (40.7) 0.654 1.09 (0.76–1.56) 114 (31.8) 160 (42.0) 0.001 0.60 (0.44–0.82) 0.009 0.74 (0.59–0.93)
CC 5 (3.0) 39 (7.8) 0.048 0.39 (0.14–0.99) 15 (4.2) 24 (6.3) 0.067 0.53 (0.27–1.05) 0.002 0.44 (0.26–0.75)
GG vs. CC+GC 0.869 1.03 (1.01–1.47) 4.7 × 10−4 1.67 (1.25–2.27) 0.001 1.45 (1.15–1.79)
GG+GC vs. CC 0.034 2.78 (1.09–7.14) 0.214 1.52 (0.78–2.94) 0.010 1.96 (0.56–3.33)
Unwinding-related
XPD(ERCC2) rs238417 n = 345 n = 372
GG 39 (23.1) 149 (29.7) 1 (Ref.) 127 (36.8) 148 (39.8) 1 (Ref.)
GC 87 (51.5) 248 (49.5) 0.191 1.33 (0.87–2.05) 158 (45.8) 155 (41.7) 0.249 1.21 (0.87–1.68) 0.491 1.09 (0.85–1.40)
CC 43 (25.4) 90 (18.0) 0.028 1.77 (1.06–2.95) 60 ((17.4) 69 (18.5) 0.796 1.06 (0.69–1.62) 0.330 1.17 (0.85–1.60)
CC+GC vs. GG 0.068 1.46 (0.97–2.20) 0.310 1.17 (0.86–1.59) 0.349 1.12 (0.86–1.41)
CC vs. GG+GC 0.056 1.50 (0.99–2.27) 0.794 0.95 (0.65–1.40) 0.437 1.12 (0.85–1.47)
Incision-related
ERCC1 rs2298881 n = 329 n = 388
CC 79 (46.7) 194 (38.7) 1 (Ref.) 104 (31.6) 145 (37.4) 1 (Ref.)
CA 58 (34.3) 224 (44.7) 0.027 0.64 (0.44–0.95) 163 (49.5) 191 (49.2) 0.302 1.19 (0.86–1.65) 0.953 0.99 (0.78–1.27)
AA 32 (18.9) 81 (16.2) 0.929 0.98 (0.60–1.59) 62 (18.8) 52 (13.4) 0.020 1.71 (1.09–2.68) 0.096 1.31 (0.95–1.81)
CA+AA vs. CC 0.076 0.73 (0.51–1.03) 0.100 1.30 (0.95–1.77) 0.563 1.07 (0.85–1.34)
AA vs. CC+CA 0.427 1.20 (0.76–1.89) 0.036 1.54 (1.03–2.31) 0.061 1.32 (0.99–1.77)
rs3212961 n = 367 n = 388
CC 64 (37.9) 143 (28.5) 1 (Ref.) 124 (33.8) 119 (30.7) 1 (Ref.)
CA 66 (39.1) 251 (50.1) 0.012 0.60 (0.40–0.89) 158 (43.1) 188 (48.5) 0.211 0.81 (0.58–1.13) 0.008 0.72 (0.56–0.92)
AA 39 (23.1) 106 (21.2) 0.422 0.83 (0.51–1.32) 85 (23.2) 81 (20.9) 0.889 1.03 (0.69–1.53) 0.600 0.92 (0.69–1.24)
CA+AA vs. CC 0.028 0.66 (0.46–0.96) 0.392 0.88 (0.64–1.19) 0.032 0.78 (0.62–0.98)
AA vs. CC+CA 0.612 1.11 (0.73–1.69) 0.399 1.16 (0.82–1.64) 0.353 1.13 (0.87–1.46)
XPG(ERCC5) rs873601 n = 369 n = 394
GG 54 (32.0) 142 (28.3) 1 (Ref.) 109 (29.5) 129 (32.7) 1 (Ref.)
GA 87 (51.5) 231 (46.1) 0.966 0.99 (0.66–1.48) 184 (49.9) 177 (44.9) 0.223 1.23 (0.88–1.71) 0.414 1.11 (0.87–1.42)
AA 28 (16.6) 126 (25.1) 0.041 0.58 (0.35–0.98) 76 (20.6) 88 (22.3) 0.897 1.03 (0.69–1.53) 0.165 0.81 (0.60–1.09)
AA+GA vs. GG 0.389 0.85 (0.58–1.24) 0.350 1.16 (0.85–1.58) 0.963 1.01 (0.80–1.27)
AA vs. GG+GA 0.022 0.59 (0.37–0.93) 0.588 0.91 (0.64–1.29) 0.038 0.76 (0.58–0.99)
a

P value was calculated by adjusted age and sex.